New hope: boosting immune system to fight lung cancer before surgery
NCT ID NCT02818920
Summary
This study tested whether giving an immunotherapy drug called pembrolizumab before and after surgery could help the immune system fight early-stage lung cancer. It involved 35 adults with stage IB-IIIA non-small cell lung cancer who were eligible for surgery. Researchers gave two doses before surgery and four after, aiming to see if this approach was safe and how it affected immune cells in the tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.